XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
الأصول والمواضيع المتأثرة
يُعرض هذا المقال بلغته الإنجليزية الأصلية.
لماذا يهم
التحليل معروض بالإنجليزية · الترجمة العربية قيد الإعداد
XORTX Therapeutics Inc. has issued a correction notice for a previously released press statement on April 17, 2025, and announced a 180-day extension to regain compliance with Nasdaq's minimum bid price deficiency. The company's shares are listed on the NASDAQ, TSXV, and Frankfurt exchanges.
التأثير المتوقع على السوق
The correction notice and extension announcement may lead to short-term market volatility, but the overall impact on the company's stock price is likely to be minimal. The extension provides XORTX with additional time to address the bid price deficiency, which may alleviate some concerns among investors.
مسار الأدلة
الأدلة
مصدر التحليل بالذكاء الاصطناعي
المعرّفات التقنية
- وسم المزوّد
- groq-llama-3.1-8b-instant
- إصدار التحليل
- groq-llama-3.1-8b-instant
- معرّف المقال
- 80
المصدر الأصلي
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that a press release that had previously been issued on April 17, 2025 was re-issued in error today. Please disregard this prior press release. XORTX announces that it received today a notice (the “Extension
اقرأ المقال كاملاً على Yahoo Finance
المقال الأصلي منشور بواسطة Yahoo Finance في 21 أكتوبر 2025. التحليل والرؤى المقدمة من AnalystMarkets AI.